



NEWS RELEASE

# SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018

11/8/2018

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that the Company will host a conference call and live audio webcast on Thursday, November 15, 2018, at 8:00 a.m. ET to report third quarter 2018 financial results and provide a corporate update.

To participate in the conference call, please dial (866) 416-7995 (domestic) or (409) 217-8225 (international) and refer to conference ID 7038536. A live webcast of the call can be accessed under "Events & Presentations" in the Investors section of the Company's website at [www.sellaslifesciences.com](http://www.sellaslifesciences.com). An archived webcast recording will be available on the SELLAS website beginning approximately two hours after the call.

About SELLAS Life Sciences Group, Inc.

SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM) and is also developing GPS as a potential treatment for multiple myeloma (MM) and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations for GPS from the U.S. Food & Drug

Administration (FDA) as well as from the European Medicines Agency for AML, MPM, and MM; GPS also received Fast Track designation for AML, MPM and MM from the FDA. SELLAS' second product candidate, nelipepimut-S (NeuVax™, NPS), is a HER2-directed cancer immunotherapy being investigated for the prevention of the recurrence of breast cancer after standard of care treatment in the adjuvant setting. NPS has received Fast Track status designation by FDA for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care.

For more information on SELLAS, please visit [www.sellaslifesciences.com](http://www.sellaslifesciences.com).

Investor Contacts:

Will O'Connor

Stern Investor Relations, Inc.

212-362-1200

**[ir@sellaslife.com](mailto:ir@sellaslife.com)**

David Moser, JD

SELLAS Life Sciences Group, Inc.

813-864-2571

**[info@sellaslife.com](mailto:info@sellaslife.com)**

Source: SELLAS Life Sciences Group